You’ve got strong data and maybe even a first-in-class idea, but do you know what it really takes to get your molecule from the bench to the bedside? What You’ll Learn: If you’re a STEM researcher, biotech founder, or academic thinking about commercialising your work, this episode breaks down the unseen steps between great science and a viable medicine.You’ll learn: • Why promising discoveries often fail — and how to spot the strategic blind spots early. • How to define your target product profile and use it to align experiments, reduce risk, and attract funding. • The “adjacent” essentials that make or break translation: IP timing, manufacturing readiness, and regulatory strategy. Hit play to learn what investors, regulators, and industry partners really want to see before backing your science. About the Guests: This episode features insights from the 2025 ARCS Drug Discovery Forum, where early-stage researchers pitched their projects to a panel of industry veterans and investors. You’ll hear from:Tim Boyle, CEO of ARCS Australia, on why upskilling and connection across the ecosystem are critical for success.Dr Wolfgang Jarolimek, Head of Drug Discovery at Syntara, on the importance of early pharmacokinetics and target engagement.Mike Lamprecht, Investment Manager at Tenmile, on designing “fail fast” experiments that protect capital and credibility.Dr Pegah Varamini, University of Sydney, and Dr Daniel Beard, University of Newcastle, on the real-life questions and lessons from taking lab discoveries closer to market. Episode Highlights: 00:00 From promising data to the maze of translation 02:15 Tim Boyle on why ARCS bridges research and industry 05:00 Why there’s no one-size-fits-all roadmap 08:00 Why “good science” isn’t enough for commercial success 10:00 The Target Product Profile — your map from lab to market 12:30 The art of “fail fast” and defining go/no-go experiments 13:45 The non-negotiables: pharmacokinetics and target engagement 16:00 When $500M fails: the Simtuzumab story 18:00 How Pegah Varamini prepared for investor questions 21:00 The GMP vs non-GMP debate — what founders should know 23:00 Parallel priorities: IP, formulation, and manufacturing 24:00 Key takeaways and what’s next in the series Reflection Time:If you had to define your Target Product Profile today, what would your “no-go” experiment look like?Which adjacent area — IP, manufacturing, or regulatory — could derail your science if ignored too long?Who do you need in your circle to ask the right questions before it’s too late?♻️ share this episode with researcher and biotechs scientists. Want to craft a career story that opens doors?I help STEMM professionals speak with clarity, confidence, and purpose and show up as thought leaders —so the right opportunities find you. Let’s connect: angeliquegreco.com.au | LinkedIn  ⭐️ Help More People Reinvent Their CareersIf you enjoyed this episode, please:✅ Leave a quick ⭐️⭐️⭐️⭐️⭐️ review on Apple Podcasts or Spotify ♻️ Share it with a friend who's questioning their path in STEM Hosted on Acast. See acast.com/privacy for more information.